Cargando…

HSP90 Inhibitor Ganetespib (STA-9090) Inhibits Tumor Growth in c-Myc-Dependent Esophageal Squamous Cell Carcinoma

PURPOSE: Currently, the paucity of classical effective pharmacological drugs to treat esophageal squamous cell carcinoma (ESCC) is a major problem. The c-Myc (MYC) protein is a promising target as it is overexpressed in ESCC. MYC is a sensitive client protein of the heat shock protein 90 (HSP90) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guan, Liuliu, Zou, Qingqing, Liu, Qian, Lin, Yiguang, Chen, Size
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156265/ https://www.ncbi.nlm.nih.gov/pubmed/32308431 http://dx.doi.org/10.2147/OTT.S245813

Ejemplares similares

Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling
por: Proia, David A., et al.
Publicado: (2011)

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies
por: Goldman, Jonathan W, et al.
Publicado: (2013)

Hsp90 Inhibitor STA9090 induced VPS35 related extracellular vesicle release and metastasis in hepatocellular carcinoma
por: Tan, Wenchong, et al.
Publicado: (2022)

Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer
por: London, Cheryl A., et al.
Publicado: (2011)

The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells
por: Gomez-Casal, Roberto, et al.
Publicado: (2015)

Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models
por: Lin, Shu-Fu, et al.
Publicado: (2017)

STA9090 as a Potential Therapeutic Agent for Liver Fibrosis by Modulating the HSP90/TβRII/Proteasome Interplay: Novel Insights from In Vitro and In Vivo Investigations
por: Mohammed, Osama A., et al.
Publicado: (2023)

HSP-90 Inhibitor Ganetespib is Synergistic with Doxorubicin in Small Cell Lung Cancer
por: Lai, Chien-Hao, et al.
Publicado: (2013)

The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer
por: He, Suqin, et al.
Publicado: (2014)

Effects of Hsp90 Inhibitor Ganetespib on Inhibition of Azole-Resistant Candida albicans
por: Yuan, Rui, et al.
Publicado: (2021)

Corrigendum: Effects of Hsp90 Inhibitor Ganetespib on Inhibition of Azole-Resistant Candida albicans
por: Yuan, Rui, et al.
Publicado: (2021)

Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice
por: Youssef, Mahmoud E., et al.
Publicado: (2023)

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib
por: Lu, Ziwen, et al.
Publicado: (2022)

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
por: Proia, David A., et al.
Publicado: (2012)

The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine
por: Lazenby, M., et al.
Publicado: (2015)

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
por: Lang, Julie E., et al.
Publicado: (2022)

Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma
por: Wu, Xinqi, et al.
Publicado: (2013)

Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
por: Friedland, Julie C., et al.
Publicado: (2013)

Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
por: HE, SUQIN, et al.
Publicado: (2012)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus
por: Liu, Yuan, et al.
Publicado: (2015)

The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer
por: Smith, Donald L., et al.
Publicado: (2014)

In vitro Cytotoxic Activities of the Oral Platinum(IV) Prodrug Oxoplatin and HSP90 Inhibitor Ganetespib against a Panel of Gastric Cancer Cell Lines
por: Klameth, Lukas, et al.
Publicado: (2017)

An Impermeant Ganetespib Analog Inhibits Extracellular Hsp90-Mediated Cancer Cell Migration that Involves Lysyl Oxidase 2-like Protein
por: McCready, Jessica, et al.
Publicado: (2014)

Evaluation of the Heat Shock Protein 90 Inhibitor Ganetespib as a Sensitizer to Hyperthermia-Based Cancer Treatments
por: Scutigliani, Enzo M., et al.
Publicado: (2022)

Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer
por: Liu, H, et al.
Publicado: (2015)

STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma
por: Heske, Christine M., et al.
Publicado: (2016)

Ganetespib: research and clinical development
por: Jhaveri, Komal, et al.
Publicado: (2015)

Inhibitors of HSP90 in melanoma
por: Mielczarek-Lewandowska, Aleksandra, et al.
Publicado: (2019)

Targeting the MYC Oncogene in Burkitt Lymphoma through HSP90 Inhibition
por: Poole, Candace J., et al.
Publicado: (2018)

The HSP-RTK-Akt axis mediates acquired resistance to Ganetespib in HER2-positive breast cancer
por: Eyermann, Christopher E., et al.
Publicado: (2021)

UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib
por: Landmann, H, et al.
Publicado: (2014)

Hsp27 and Hsp70 Expression in Esophageal Squamous
por: Luz, Caio Cesar Floriano, et al.
Publicado: (2017)

Ganetespib radiosensitization for liver cancer therapy
por: Chettiar, Sivarajan T., et al.
Publicado: (2016)

Hypoxia attenuates Hsp90 inhibitor 17-DMAG-induced cyclin B1 accumulation in hepatocellular carcinoma cells
por: Zhang, Jianming, et al.
Publicado: (2016)

MicroRNA-27a downregulates the expression of Hsp90 and enhances the radiosensitivity in esophageal squamous cell carcinoma
por: Wang, Xintong, et al.
Publicado: (2019)

Hsp90 Inhibitors Prevent HSV-1 Replication by Directly Targeting UL42-Hsp90 Complex
por: Qin, Shurong, et al.
Publicado: (2022)

HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation
por: Kijima, Toshiki, et al.
Publicado: (2018)

Silence of HDAC6 suppressed esophageal squamous cell carcinoma proliferation and migration by disrupting chaperone function of HSP90
por: Tao, Hua, et al.
Publicado: (2018)

Extracellular Hsp90α clinically correlates with tumor malignancy and promotes migration and invasion in esophageal squamous cell carcinoma
por: Wang, Xintong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_spjps90dlj6nnk1r19d5ssije6